|
|
|
| Single case randomized controlled research of Modified Huangqi Chifeng Decoction in the treatment of proteinuria due to IgA nephropathy |
| JIAO Zhina ZHAO Mingming ZHANG Yu▲ LI Liusheng SI Yuan |
| Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China |
|
|
|
Abstract Objective To observe the efficacy and safety of Modified Huangqi Chifeng Decoction in the treatment of proteinuria due to IgA nephropathy. Methods The cases came from the Outpatient Department of Nephrology in Xiyuan Hospital, China Academy of Chinese Medical Sciences from December 2011 to December 2012. 5 cases of patients with IgA nephropathy with mild to moderate proteinuria, normal kidney function and syndrome of blood stasis due to qi deficiency were enrolled. By using single case randomized controlled design, Modified Huangqi Chifeng Decoction combined with Telmisartan was applied in the treatment period and single Telmisartan was applied in the control period. The efficacy indices were 24-hour urine protein quantification and TCM symptom scores, the safety indices were liver and kidney function and blood routine examination. Results The TCM symptom scores of each case in the treatment period were significantly reduced in different degrees compared with those of control period (P ＜ 0.05); after TCM symptom scores of 5 patients were integrated, the treatment period was significantly improved compared with those of control period (P ＜ 0.05). The 24-hour urine protein quantification of each patient in the treatment period was significantly lower than those of control period (P ＜ 0.05), after 24-hour urine protein quantification of 5 patients was integrated, the treatment period was significantly less than that of control period (P ＜ 0.05). Conclusion Modified Huangqi Chifeng Decoction in treatment of proteinuria due to IgA nephropathy is safe and effective, and it is feasible to use single case randomized control design in clinical research of TCM.
|
|
|
|
|
|
[1] 谌贻璞.肾内科学[M].北京：人民卫生出版社，2008：13-16.
[2] McGrogan A，Franssen CF，de Vries CS. The incidence of primary glomerulonephritis worldwide： a systematic review of the literature [J]. Nephrol Dial Transplant，2011， 26（2）：414-430.
[3] Xu X，Ning Y，Shang W，et al. Analysis of 4931 renal biopsy data in central China from 1994 to 2014 [J]. Ren Fail，2016， 38（7）：1021-1030.
[4] Cattran DC，Feehally J，Cook HT，et al. Kidney disease: Improving global outcomes（KDIGO）glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis [J]. Kidney International Supplements，2012，2（2）：139-274.
[5] 温长路，刘玉玮，温武兵.医林改错识要[M].北京：中医古籍出版社，2002：157-158.
[6] 王允亮，张昱，王洪霞，等.加味黄芪赤风汤对阿霉素肾病大鼠蛋白尿及血清NO，ET-1和TGF-β1的影响[J].世界中西医结合杂志，2010，5（10）：852-854.
[7] 王允亮，张昱，王洪霞，等.加味黄芪赤风汤对阿霉素肾病大鼠蛋白尿及肾脏皮质SOD和MDA的影响[J].中国中医基础医学杂志，2011，17（5）：505-506.
[8] 王海燕.肾脏病学[M].3版.北京：人民卫生出版社，2008：993-1008.
[9] 郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2001：156-162.
[10] 李江，翟静波，商洪才，等.单病例随机对照试验的起源与发展[J].中国循证医学杂志，2017，17（2）：235-238.
[11] 陈新林，李海文，刘凤斌，等.单病例随机对照试验的设计和评价方法[J].中国循证医学杂志，2016，16（2）：242-245.
[12] 刘志刚，柴程芝，朱欣佚.葛根汤治疗原发性痛经的多基线单病例随机对照试验[J].中华中医药杂志，2015， 30（7）：2473-2476.
[13] 王辉，陈静，商洪才.单病例随机对照试验设计在中医药临床研究的探索与实践[J].中华中医药杂志，2010， 25（11）：1823-1828.
[14] Samuel JP，Bell CS. Unique Study Designs in Nephrology：N-of-1 Trials and Other Designs [J]. Adv Chronic Kidney Dis，2016，23（6）：351-354.
[15] 刘建平，张枚.单病例随机对照试验设计在中医药研究中的应用[J].中国中医药信息杂志，2002，9（6）：66-68.
[16] 许卫华.单病例随机对照试验在中医药临床研究中的应用与思考[J].中国临床药理学与治疗学，2005，10（11）：1315-1317.
[17] 于大君，翁维良，陆芳，等.慢性肾脏病Ⅲ期单病例随机对照临床试验[J].中医杂志，2012，53（3）：222-224.
[18] 中国中西医结合学会肾脏疾病专业委员会.IgA肾病西医诊断和中医辨证分型的实践指南[J].中国中西医结合杂志，2013，33（5）：583-585.
[19] 李刘生，赵明明，张昱.张昱基于“虚-风-瘀-毒”复杂病机网络诊治IgA肾病的经验[J].世界中西医结合杂志，2017，12（4）：450-472.
[20] 焦志娜，张昱，李澎，等.加味黄芪赤风汤对小鼠系膜细胞增殖及分泌细胞外基质的影响[J].世界中西医结合杂志，2016，11（7）：941-944.
[21] 刘红霞，张昱，李澎，等.加味黄芪赤风汤含药血清对LPS诱导的小鼠肾小球系膜细胞ColⅣ、MMP-2及TIMP-2表达的影响[J].中国中西医结合杂志，2016，36（5）：592-596.
[22] 高艳红，张昱，李澎，等.基于TGF-β1/Smad信号通路的加味黄芪赤风汤抗肾脏纤维化机制研究[J].中国中西医结合杂志，2016，36（12）：1503-1506. |
|
|
|
